DRIO · XBRL financial data

DarioHealth financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (DRIO's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cost of goods and services sold	5,063	12,444	18,001	14,368	13,773	9,694
Gross profit	2,513	3,963	9,655	5,984	13,267	12,665
Research and development	4,433	17,219	19,649	20,248	24,179	13,791
General and administrative	12,756	23,532	16,493	18,140	20,482	15,191
Total operating expenses	32,416	80,457	66,465	62,173	71,011	49,320
Operating income (loss)	(29,903)	(76,494)	(56,810)	(56,189)	(57,744)	(36,655)
Interest income	61	44	506	1,868	1,116	943
Interest expense	—	—	1,876	—	—	3,020
Other income (expense)	—	—	—	—	13,145	(1,934)
Income tax expense (benefit)	—	32	4	64	(1,852)	105
Net income (loss)	(29,445)	(76,761)	(62,193)	(59,427)	(42,747)	(41,714)
Earnings per share, basic‡ USD per share	80.20	81.40	50.80	38.60	12.20	10.12
Earnings per share, diluted‡ USD per share	80.20	81.40	50.80	38.60	12.20	10.12
Weighted average shares, basic‡ thousands of shares	298	830	1,182	1,419	2,452	3,983
Weighted average shares, diluted‡ thousands of shares	298	830	1,182	1,419	2,452	3,983

‡ Per-share figures and share counts are adjusted for the 1-for-20 stock split (August 2025); filings made before it reported them unadjusted.

Fiscal years (DRIO's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	28,590	35,808	49,357	36,797	27,764	21,803
Short-term investments	—	—	—	—	—	4,214
Inventory	2,293	6,228	7,956	5,062	4,753	4,316
Prepaid and other current assets	2,934	2,067	1,630	2,024	2,336	2,361
Total current assets	34,128	45,605	65,524	47,330	40,529	35,067
Property and equipment, net	576	702	788	899	709	549
Right-of-use asset	498	287	1,206	967	1,065	717
Goodwill	0	41,640	41,640	41,640	57,427	57,427
Total assets	35,407	100,771	119,191	96,389	118,884	110,075
Accrued liabilities	880	4,398	2,185	2,227	1,940	2,402
Current portion of long-term debt	—	—	8,823	3,954	5,451	—
Total current liabilities	7,034	14,376	19,350	12,493	16,635	9,323
Long-term debt	—	0	18,105	24,591	23,472	30,747
Lease liability, non-current	222	21	827	885	765	571
Accumulated deficit	(143,248)	(222,014)	(285,850)	(349,361)	(390,343)	(452,078)
Total stockholders' equity	28,151	85,549	79,999	58,144	72,019	67,922
Total liabilities and equity	35,407	100,771	119,191	96,389	118,884	110,075
Common shares outstanding (cover page)‡ thousands of shares	764	1,091	1,294	1,472	2,078	7,300

‡ Per-share figures and share counts are adjusted for the 1-for-20 stock split (August 2025); filings made before it reported them unadjusted.

Fiscal years (DRIO's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(29,445)	(76,761)	(62,193)	(59,427)	(42,747)	(41,714)
Stock-based compensation	—	—	—	—	46	—
Net cash from operating activities	(17,736)	(50,409)	(47,845)	(30,379)	(38,562)	(25,941)
Purchases of property and equipment	118	261	442	584	138	142
Net cash from investing activities	(1,622)	(8,134)	(573)	(547)	(8,934)	(4,342)
Proceeds from issuing common stock	27,548	64,877	38,288	—	—	—
Proceeds from issuing equity	27,548	—	—	—	—	—
Share repurchases	—	—	134	—	—	—
Repayments of long-term debt	—	—	—	27,833	—	31,515
Net cash from financing activities	27,548	65,766	61,940	18,253	38,531	24,313

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
DarioHealth	6,634	not reported	(6,083)*	9.8M	2.3 quarters	Q2 FY26 10-QJun 30, 2026
electroCore	8,501	9,450	(3,518)*	9.0M	2.9 quarters	Q2 FY26 10-QJun 30, 2026
Nephros	4,697	6,017	681*	10.9M	—	Q2 FY26 10-QJun 30, 2026
RenovoRx	9,479	909	(2,867)*	45.1M	3.3 quarters	Q2 FY26 10-QJun 30, 2026
Femasys	1,444	332	(3,936)*	8.4M	0.4 quarters	Q2 FY26 10-QJun 30, 2026
Precision Optics	9,841	8,774*	(649)*	11.0M	15.2 quarters	Q4 FY26 10-KJun 30, 2026
Neuroone Medical Technologies	2,048	1,973	(1,082)*	9.1M	1.9 quarters	Q3 FY26 10-QJun 30, 2026
United Health Products	24	0	(138)*	262.7M	0.2 quarters	Q2 FY26 10-QJun 30, 2026
Cerenome	2,366	411	(7,132)*	7.6M	1.2 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.